Literature DB >> 22454296

Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience.

Binita M Kamath1, Wanrong Yin, Heather Miller, Ravinder Anand, Elizabeth B Rand, Estella Alonso, John Bucuvalas.   

Abstract

Alagille syndrome (ALGS) is a multisystem disorder that manifests as childhood cholestasis. Reports of liver transplantation (LT) for patients with ALGS have come largely from single centers, which have reported survival rates of 57% to 79%. The aim of this study was to determine LT outcomes for patients with ALGS. We performed a retrospective analysis of the Studies of Pediatric Liver Transplantation database, which contains information about 3153 pediatric LT recipients. Data were available for 91 patients with ALGS and for 236 age-matched patients with biliary atresia (BA). The frequency of complex cardiac anomalies was lower in the LT group with ALGS versus published ALGS series (5% versus 13%). The pretransplant glomerular filtration rate (GFR) was <90 mL/minute/1.73 m(2) in 18% of the LT patients with ALGS and in 5% of the LT patients with BA (P < 0.001). The height deficit at listing was worse for the ALGS patients (66%) versus the BA patients (22%). The 1-year patient survival rates were 87% for the ALGS patients and 96% for the BA patients (P = 0.002). The deaths in the ALGS group mostly occurred within the first 30 days. No pretransplant factors associated with death were identified in the ALGS group. A survival analysis revealed that biliary (P = 0.02), vascular (P < 0.001), central nervous system (CNS; P < 0.001), and renal complications (P < 0.001) after LT were associated with death in the ALGS group. Renal insufficiency in the ALGS patients worsened after LT, and at 1 year, GFR was <90 mL/minute/1.73 m(2) in 22% of the LT patients with ALGS but in only 8% of the patients with BA (P = 0.0014). More LT pediatric patients with ALGS either were currently receiving special education (50% versus 30% for BA patients, P = 0.02) or had received special education in the past (60% versus 36%, P = 0.01). Vascular, CNS, and renal complications were increased in the ALGS patients after LT, and this reflected multisystem involvement. Although the 1-year survival rate was modestly lower for the ALGS patients versus the BA patients, the clustering of deaths within the first 30 days is notable and warrants increased vigilance and further investigation.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22454296     DOI: 10.1002/lt.23437

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  21 in total

1.  JAGGED1 gene variations in Chinese twin sisters with Alagille syndrome.

Authors:  Xinbao Xie; Yi Lu; Xiaohong Wang; Bingbing Wu; Hui Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 2.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

3.  Spectrum of cerebral arterial and venous abnormalities in Alagille syndrome.

Authors:  Candice D Carpenter; Luke L Linscott; James L Leach; Sudhakar Vadivelu; Todd Abruzzo
Journal:  Pediatr Radiol       Date:  2018-01-23

4.  Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey.

Authors:  Reinhard E Friedrich; Jozef Zustin; Andreas M Luebke; Thorsten Rosenbaum; Martin Gosau; Christian Hagel; Felix K Kohlrusch; Ilse Wieland; Martin Zenker
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

5.  Directed differentiation of cholangiocytes from human pluripotent stem cells.

Authors:  Mina Ogawa; Shinichiro Ogawa; Christine E Bear; Saumel Ahmadi; Stephanie Chin; Bin Li; Markus Grompe; Gordon Keller; Binita M Kamath; Anand Ghanekar
Journal:  Nat Biotechnol       Date:  2015-07-13       Impact factor: 54.908

6.  Early life predictive markers of liver disease outcome in an International, Multicentre Cohort of children with Alagille syndrome.

Authors:  Marialena Mouzaki; Lee M Bass; Ronald J Sokol; David A Piccoli; Claudia Quammie; Kathleen M Loomes; James E Heubi; Paula M Hertel; Rene Scheenstra; Katryn Furuya; Erika Kutsch; Nancy B Spinner; Kristen N Robbins; Veena Venkat; Philip Rosenthal; Joseph Beyene; Alastair Baker; Binita M Kamath
Journal:  Liver Int       Date:  2015-08-18       Impact factor: 5.828

7.  Paediatric cholestatic liver disorders for the adult gastroenterologist: a practical guide.

Authors:  Claire Kelly; Jeremy Shanika Nayagam; Stamatina Vogli; Marianne Samyn; Deepak Joshi
Journal:  Frontline Gastroenterol       Date:  2020-08-03

8.  Clinical Practice Guidelines for Liver Transplantation in Saudi Arabia.

Authors:  Faisal A Abaalkhail; Mohammed I Al Sebayel; Mohammed A Shagrani; Wael A O'Hali; Nasser M Almasri; Abduljaleel A Alalwan; Mohammed Y Alghamdi; Hamad Al-Bahili; Mohammed S AlQahtani; Saleh I Alabbad; Waleed K Al-Hamoudi; Saleh A Alqahtani
Journal:  Saudi Med J       Date:  2021-09       Impact factor: 1.422

9.  Quality of Life and Its Determinants in a Multicenter Cohort of Children with Alagille Syndrome.

Authors:  Binita M Kamath; Zhen Chen; Rene Romero; Emily M Fredericks; Estella M Alonso; Ronen Arnon; James Heubi; Paula M Hertel; Saul J Karpen; Kathleen M Loomes; Karen F Murray; Philip Rosenthal; Kathleen B Schwarz; Girish Subbarao; Jeffrey H Teckman; Yumirle P Turmelle; Kasper S Wang; Averell H Sherker; Ronald J Sokol; John C Magee
Journal:  J Pediatr       Date:  2015-06-06       Impact factor: 4.406

Review 10.  Renal involvement and the role of Notch signalling in Alagille syndrome.

Authors:  Binita M Kamath; Nancy B Spinner; Norman D Rosenblum
Journal:  Nat Rev Nephrol       Date:  2013-06-11       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.